Home › Myasthenia Gravis › NCT07501702
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
RecruitingPhase 2
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Age greater than or equal to (\>=) 18 years * Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * History of thymic surgery within 6 months of screening * History of malignancy within the last 5 years * Additional exclusion criteria are defined in the protocol Other protocol defined Inclusion/Exclusion criteria will apply.
About the study
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
What is being tested
- Povetacicept (drug)
- Placebo (drug)
Sponsor: Vertex Pharmaceuticals Incorporated · Participants: 30 · Started: May 13, 2026
Contact the study team
- Medical Information · Phone: 617-341-6777
Official record on ClinicalTrials.gov — NCT07501702
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.